Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06248606 | Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases | recruiting | Phase 2 | 30 | Ryan Gentzler, MDOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 50 | Emory UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07001618 |
| recruiting |
| Phase 2 |
| 162 |
| Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Apr 3, 2026 |
| clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT07354061 | Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)(TD-ENSEMBLE) | recruiting | Phase 1 / Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505173 | Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer(HOPE-WBRT) | recruiting | Phase 2 | 74 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06424067 | Phase 2 Study of Fingolimod in Lung Cancers | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492342 | Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC(K-NADIR) | recruiting | Phase 2 | 30 | Jianxing HeOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05805631 | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | recruiting | Phase 2 | 23 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05669846 | Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC | recruiting | Phase 2 | 26 | Diwakar DavarOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07218601 | Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07336732 | Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations(KANNON-5) | recruiting | Phase 2 | 40 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04499053 | Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07467863 | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC(DUO-NK-NSCLC) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05798845 | The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer | recruiting | Phase 2 | 124 | Shanghai Chest HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06775743 | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06951646 | ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) | recruiting | Phase 2 | 70 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01803542 | Stereotactic Radiotherapy (SBRT) of Lung Metastasis(SBRT Lung) | recruiting | Phase 2 | 200 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05672108 | Phase II Trial of Lung Chemoemobolization | recruiting | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07264816 | A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC | recruiting | Phase 2 | 80 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06275360 | Repositioning Immunotherapy in VetArans With Lung Cancer(RIVAL) | recruiting | Phase 2 | 25 | VA Office of Research and DevelopmentFED | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06918132 | Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer(N-PLANC) | recruiting | Phase 2 | 60 | Mayo ClinicOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07428044 | A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer | recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 23, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07408635 | IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer | recruiting | Phase 2 | 43 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410975 | Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer | recruiting | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06731270 | Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07082179 | A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 33 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07392658 | Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.(AMICUTE) | recruiting | Phase 2 | 33 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03953144 | Synapse 3D With Intravascular Indocyanine Green | recruiting | Phase 1 / Phase 2 | 32 | St. Joseph's Healthcare HamiltonOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04467723 | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | recruiting | Phase 1 / Phase 2 | 25 | University of Kansas Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05467748 | EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 66 | VA Office of Research and DevelopmentFED | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06810609 | Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC(InDuRanS) | recruiting | Phase 2 | 176 | University Hospital, BonnOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07362940 | A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib | recruiting | Phase 1 / Phase 2 | 110 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies(PRISM) | recruiting | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy | recruiting | Phase 2 | 41 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330050 | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330596 | QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC | recruiting | Phase 2 | 96 | Anhui Provincial Cancer HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05613413 | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)(LUNG-IST-127) | recruiting | Phase 2 | 36 | University of Illinois at ChicagoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2026source: clinicaltrials